Screener
Dianthus Therapeutics DNTH Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Dianthus Therapeutics’s reported figures.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
FAQ
- What is Dianthus Therapeutics's enterprise value?
- Dianthus Therapeutics (DNTH) reported enterprise value of $3.82B in Q1 2026.
- How has Dianthus Therapeutics's enterprise value changed year-over-year?
- Dianthus Therapeutics's enterprise value increased by 564.9% year-over-year, from $574.03M to $3.82B.
- What is the long-term trend for Dianthus Therapeutics's enterprise value?
- Over 3 years (2022 to 2025), Dianthus Therapeutics's enterprise value has grown at a 254.5% compound annual growth rate (CAGR), from $38.55M to $1.72B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Dianthus Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude